Clarus Builds Investment Team

Feb 10 2006 | 10:18pm ET

Clarus Ventures, a global life sciences venture capital firm with offices in San Francisco and Cambridge, Mass., has filled out its investment team to manage its first fund, which closed in December with $500 million in committed capital. The firm has hired three principals and a controller to help manage the fund and Robert Liptak, managing director, said the firm is looking to make one additional hire.

The newly-formed team includes Emmett Cunningham, Michele Park and Scott Requadt, who have joined the firm as principals, and Danielle Bechard, who has joined as controller.

Prior to joining the firm's San Francisco office, Cunningham was senior vice president of medical strategy at Eyetech Pharmaceuticals, where he played a leadership role in the development and approval of Macugen, a drug used to help age-related macular degeneration.

Park joins the San Francisco office of Clarus from Credit Suisse First Boston, where she was an analyst covering large, medium and small capitalization biotechnology companies with a focus on companies with oncologic and anti-infective products.

Requadt joins the Cambridge office from TransForm Pharmaceuticals, where he was director of business development.

Finally, Bechard joins the Cambridge office from the McDonald's Corporation, where she was responsible for franchisee analysis.

The fund will invest in predominantly later-stage biotechnology firms, Liptak said.


In Depth

bfinance: Fees Falling Across Asset Classes, Yet Overall Investor Costs Still Climbing

May 16 2017 | 9:53pm ET

Despite unprecedented attention on fees, new research from investment consultancy...

Lifestyle

CFA Institute To Add Computer Science To Exam Curriculum

May 24 2017 | 9:25pm ET

Starting in 2019, financial industry executives sitting for the coveted Chartered...

Guest Contributor

Risk-Based Compliance: Why Oversight Of Outsourcing Is Critical

May 10 2017 | 7:02pm ET

Compliance is notoriously one of the trickiest middle office functions for funds...

 

From the current issue of